{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:22:00Z","timestamp":1792167720825,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Whether plasma aldosterone concentration (PAC) is associated with incident cardiovascular disease (CVD) remains unclear in hypertensive patients, particularly after excluding those with primary aldosteronism. This study evaluates the association between PAC and incident CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included hypertensive patients admitted to the hypertension center between January 1, 2014, and December 31, 2017, who had PAC measurements. Incident events encompassed both cardiac events and stroke. Cox proportional hazards models were used to evaluate the association between PAC and the outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8653 hypertensive patients were included in this study. During a median follow-up of 5.2 years, 737 cases of incident CVD occurred. The incidence of the outcome increased with higher quartiles of PAC. Individuals in the highest quartile of PAC had a 51% increased risk of CVD (HR 1.51, 95% CI 1.23\u20131.86) compared to those in the lowest quartile. The overall results remained stable and consistent in the stratification and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher PAC was associated with increased risk of CVD in hypertensive patients, irrespective of concomitant primary aldosteronism. These findings suggest that PAC might be a target for early prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1791569","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:21:00Z","timestamp":1776918060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between aldosterone and the risk of cardiovascular disease in hypertensive patients: a cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lin","family":"Gan","sequence":"first","affiliation":[{"name":"Graduate School, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulalibieke","family":"Heizhati","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yao","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Liu","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hong","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hypertension Center of People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region \u201cHypertension Research Laboratory\u201d, Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011106","article-title":"Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology","volume":"68","author":"Jaisser","year":"2015","journal-title":"Pharmacol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2014","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065","article-title":"The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038714","article-title":"Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis","volume":"14","author":"Huang","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaf156","article-title":"Rethinking Primary Aldosteronism: The 2025 John H. Laragh Research Award","volume":"39","author":"Hundemer","year":"2025","journal-title":"Am J Hypertens"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study","volume":"149","author":"Hundemer","year":"2023","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0882","article-title":"The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of Serum Aldosterone and Plasma Renin Activity With Ambulatory Blood Pressure in African Americans: The Jackson Heart Study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a Mediator of Cardiovascular Damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.05.012","article-title":"Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study","volume":"5","author":"Joseph","year":"2017","journal-title":"JACC Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055373","article-title":"Multiple biomarkers for the prediction of first major cardiovascular events and death","volume":"355","author":"Wang","year":"2006","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2011","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"G\u00fcder","year":"2007","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013790","article-title":"Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial","volume":"8","author":"Kumar","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.05.117","article-title":"Renin and aldosterone are not associated with vulnerable plaque characteristics in patients with carotid artery disease","volume":"68","author":"Hillaert","year":"2018","journal-title":"J Vasc Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1017177","article-title":"Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data","volume":"13","author":"Gan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18342","article-title":"Higher Plasma Aldosterone Concentrations Are Associated With Elevated Risk of Aortic Dissection and Aneurysm: a Case-Control Study","volume":"79","author":"Zhu","year":"2022","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.20953","article-title":"Hypertension in Primary Aldosteronism Is Initiated by Salt-Induced Increases in Vascular Resistance With Reductions in Cardiac Output","volume":"80","author":"Kurtz","year":"2023","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0030-z","article-title":"Endothelial dysfunction and angiogenesis impairment in the ageing vasculature","volume":"15","author":"Ungvari","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01967","article-title":"Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness","volume":"63","author":"Galmiche","year":"2013","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211025240","article-title":"Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension","volume":"11","author":"Menon","year":"2021","journal-title":"Pulm Circ"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1791569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:21:01Z","timestamp":1776918061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1791569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1791569"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1791569","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1791569"}}